Kidney diseases in HIV-infected patients;Néphropathies rencontrées au cours de l'infection par le virus de l'immunodéficience humaine (VIH)

Nephrologie et Therapeutique

Volumn 5, Issue 6, 2009, Pages 576-591

  Tourret, Jérôme ^a   Tostivint, Isabelle ^a   Deray, Gilbert ^a   Isnard Bagnis, Corinne ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Antiretroviral therapy; Drug nephrotoxicity; HIV; HIV associated nephropathy; Proteinuria; Viral co infections

Indexed keywords

ACICLOVIR; ADEFOVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; CIDOFOVIR; CIPROFLOXACIN; CORTICOSTEROID; COTRIMOXAZOLE; CREATININE; CYCLOSPORIN; DIDANOSINE; FOSCARNET; GANCICLOVIR; INDINAVIR; INTERFERON; PEGINTERFERON; PHENYTOIN; PREDNISONE; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SULFADIAZINE; TENOFOVIR; VALACICLOVIR;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CHRONIC KIDNEY FAILURE; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; CRYSTALLURIA; DRUG TOLERABILITY; FANCONI RENOTUBULAR SYNDROME; GLOMERULUS FILTRATION RATE; GRANULOMATOSIS; HEART INFARCTION; HEMATURIA; HEMOLYTIC UREMIC SYNDROME; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOKALEMIA; HYPOPHOSPHATEMIA; HYPOURICEMIA; IMMUNE COMPLEX NEPHRITIS; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY TUBULE ACIDOSIS; KIDNEY TUBULE DISORDER; LABORATORY TEST; LEUKOCYTURIA; LIFE EXPECTANCY; LIPODYSTROPHY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; METABOLIC ACIDOSIS; NEPHRITIS; NEPHROGENIC DIABETES INSIPIDUS; NEPHROSCLEROSIS; NEPHROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PROGNOSIS; PROTEINURIA; RENAL DIABETES; SCREENING; SHORT SURVEY; SIDE EFFECT; SYSTEMIC DISEASE; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; URINARY TRACT OBSTRUCTION;

ANTI-HIV AGENTS; DECISION TREES; HIV INFECTIONS; HUMANS; KIDNEY DISEASES;

EID: 71249163372     PISSN: 17697255     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nephro.2009.02.007     Document Type: Short Survey

References (111)

1. Gardner L.I., Holmberg S.D., Williamson J.M., Szczech L.A., Carpenter C.C., Rompalo A.M., et al. Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women. J Acquir Immune Defic Syndr 32 (2003) 203-209
2. Emem C.P., Arogundade F., Sanusi A., Adelusola K., Wokoma F., and Akinsola A. Renal disease in HIV-seropositive patients in Nigeria: an assessment of prevalence, clinical features and risk factors. Nephrol Dial Transplant 23 (2008) 741-746
3. Fernando S.K., Finkelstein F.O., Moore B.A., and Weissman S. Prevalence of chronic kidney disease in an urban HIV infected population. Am J Med Sci 335 (2008) 89-94
4. Wyatt C.M., Winston J.A., Malvestutto C.D., Fishbein D.A., Barash I., Cohen A.J., et al. Chronic kidney disease in HIV infection: an urban epidemic. AIDS 21 (2007) 2101-2103
5. Szczech L.A., Gange S.J., van der Horst C., Bartlett J.A., Young M., Cohen M.H., et al. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int 61 (2002) 195-202
6. D'Agati V., and Appel G.B. HIV infection and the kidney. J Am Soc Nephrol 8 (1997) 138-152
7. Weiner N.J., Goodman J.W., and Kimmel P.L. The HIV-associated renal diseases: current insight into pathogenesis and treatment. Kidney Int 63 (2003) 1618-1631
8. Kimmel P.L., Barisoni L., and Kopp J.B. Pathogenesis and treatment of HIV-associated renal diseases: lessons from clinical and animal studies, molecular pathologic correlations, and genetic investigations. Ann Intern Med 139 (2003) 214-226
9. Soriano-Rosas J., Avila-Casado M.C., Carrera-Gonzalez E., Chavez-Mercado L., Cruz-Ortiz H., and Rojo J. AIDS-associated nephropathy: 5-year retrospective morphologic analysis of 87 cases. Pathol Res Pract 194 (1998) 567-570
10. Lanjewar D.N., Ansari M.A., Shetty C.R., Maheshwari M.B., and Jain P. Renal lesions associated with AIDS - an autopsy study. Indian J Pathol Microbiol 42 (1999) 63-68
11. Tostivint I., Mougenot B., Flahault A., Vigneau C., Costa M.A., Haymann J.P., et al. Adult haemolytic and uraemic syndrome: causes and prognostic factors in the last decade. Nephrol Dial Transplant 17 (2002) 1228-1234
12. D'Agati V., and Appel G.B. Renal pathology of human immunodeficiency virus infection. Semin Nephrol 18 (1998) 406-421
13. Maslo C., Peraldi M.N., Desenclos J.C., Mougenot B., Cywiner-Golenzer C., Chatelet F.P., et al. Thrombotic microangiopathy and cytomegalovirus disease in patients infected with human immunodeficiency virus. Clin Infect Dis 24 (1997) 350-355
14. Rerolle J.P., Canaud G., Fakhouri F., Aaron L., Morelon E., Peraldi M.N., et al. Thrombotic microangiopathy and hypothermia in an HIV-positive patient: importance of cytomegalovirus infection. Scand J Infect Dis 36 (2004) 234-237
15. Cheng V.C., Yuen K.Y., Chan W.M., Wong S.S., Ma E.S., and Chan R.M. Immunorestitution disease involving the innate and adaptive response. Clin Infect Dis 30 (2000) 882-892
16. Jehle A.W., Khanna N., Sigle J.P., Glatz-Krieger K., Battegay M., Steiger J., et al. Acute renal failure on immune reconstitution in an HIV-positive patient with miliary tuberculosis. Clin Infect Dis 38 (2004) e32-e35
17. Izzedine H., Launay-Vacher V., Isnard-Bagnis C., and Deray G. Drug-induced Fanconi's syndrome. Am J Kidney Dis 41 (2003) 292-309
18. Daudon M., Estepa L., Viard J.P., Joly D., and Jungers P. Urinary stones in HIV-1-positive patients treated with indinavir. Lancet 349 (1997) 1294-1295
19. Gagnon R.F., Alli A.I., and Watters A.K. Tsoukas CM: Indinavir crystalluria. Kidney Int 70 (2006) 2047
20. Tashima K.T., Horowitz J.D., and Rosen S. Indinavir nephropathy. N Engl J Med 336 (1997) 138-140
21. Izzedine H., Launay-Vacher V., and Deray G. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 45 (2005) 804-817
22. Izzedine H., M'Rad M.B., Bardier A., Daudon M., and Salmon D. Atazanavir crystal nephropathy. AIDS 21 (2007) 2357-2358
23. Pacanowski J., Poirier J.M., Petit I., Meynard J.L., and Girard P.M. Atazanavir urinary stones in an HIV-infected patient. AIDS 20 (2006) 2131
24. Chugh S., Bird R., and Alexander E.A. Ritonavir and renal failure. N Engl J Med 336 (1997) 138
25. Deray G., Bochet M., Katlama C., and Bricaire F. Nephrotoxicity of ritonavir. Presse Med 27 (1998) 1801-1803
26. Witzke O., Plentz A., Schafers R.F., Reinhardt W., Heemann U., and Philipp T. Side-effects of ritonavir and its combination with saquinavir with special regard to renal function. AIDS 11 (1997) 836-838
27. Creput C., Gonzalez-Canali G., Hill G., Piketty C., Kazatchkine M., and Nochy D. Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS 17 (2003) 935-937
28. Karras A., Lafaurie M., Furco A., Bourgarit A., Droz D., Sereni D., et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 36 (2003) 1070-1073
29. Rollot F., Nazal E.M., Chauvelot-Moachon L., Kelaidi C., Daniel N., Saba M., et al. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine. Clin Infect Dis 37 (2003) e174-e176
30. Verhelst D., Monge M., Meynard J.L., Fouqueray B., Mougenot B., Girard P.M., et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 40 (2002) 1331-1333
31. Izzedine H., Isnard-Bagnis C., Hulot J.S., Vittecoq D., Cheng A., Jais C.K., et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 18 (2004) 1074-1076
32. Peyriere H., Reynes J., Rouanet I., Daniel N., de Boever C.M., Mauboussin J.M., et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 35 (2004) 269-273
33. Nelson M.R., Katlama C., Montaner J.S., Cooper D.A., Gazzard B., Clotet B., et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 21 (2007) 1273-1281
34. Cihlar T., Ray A.S., Laflamme G., Vela J.E., Tong L., Fuller M.D., et al. Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antivir Ther 12 (2007) 267-272
35. Ray A.S., Cihlar T., Robinson K.L., Tong L., Vela J.E., Fuller M.D., et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 50 (2006) 3297-3304
36. Conn J., Colman P., Brown G., Street A., and Bate K. Nephrogenic diabetes insipidus associated with foscarnet - a case report. J Antimicrob Chemother 37 (1996) 1179-1181
37. Farese Jr. R.V., Schambelan M., Hollander H., Stringari S., and Jacobson M.A. Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis. Ann Intern Med 112 (1990) 955-956
38. Navarro J.F., Quereda C., Quereda C., Gallego N., Antela A., Mora C., et al. Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy. Am J Kidney Dis 27 (1996) 431-434
39. Izzedine H., Launay-Vacher V., and Deray G. Anti-viraux. Guide de prescription des médicaments chez le patient insuffisant rénal (2003), Éditions International, Paris
40. Jacobson M.A. Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 337 (1997) 105-114
41. Ho E.S., Lin D.C., Mendel D.B., and Cihlar T. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol 11 (2000) 383-393
42. Ohta S., Yokoyama H., Wada T., Sakai N., Shimizu M., Kato T., et al. Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy. Am J Kidney Dis 33 (1999) 1040-1048
43. Izzedine H., Hulot J.S., Launay-Vacher V., Marcellini P., Hadziyannis S.J., Currie G., et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int 66 (2004) 1153-1158
44. Tanji N., Tanji K., Kambham N., Markowitz G.S., Bell A., and D'Agati V.D. Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol 32 (2001) 734-740
45. Nadler R.B., Rubenstein J.N., Eggener S.E., Loor M.M., and Smith N.D. The etiology of urolithiasis in HIV infected patients. J Urol 169 (2003) 475-477
46. Rao T.K., Filippone E.J., Nicastri A.D., Landesman S.H., Frank E., Chen C.K., et al. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med 310 (1984) 669-673
47. Ross M.J., and Klotman P.E. Recent progress in HIV-associated nephropathy. J Am Soc Nephrol 13 (2002) 2997-3004
48. Winston J.A., Burns G.C., and Klotman P.E. The human immunodeficiency virus (HIV) epidemic and HIV-associated nephropathy. Semin Nephrol 18 (1998) 373-377
49. Vigneau C., Guiard-Schmid J.B., Tourret J., Flahault A., Rozenbaum W., Pialoux G., et al. The clinical characteristics of HIV-infected patients receiving dialysis in France between 1997 and 2002. Kidney Int 67 (2005) 1509-1514
50. Lucas G.M., Eustace J.A., Sozio S., Mentari E.K., Appiah K.A., and Moore R.D. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 18 (2004) 541-546
51. Schwartz E.J., Szczech L.A., Ross M.J., Klotman M.E., Winston J.A., and Klotman P.E. Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol 16 (2005) 2412-2420
52. Winston J.A., Klotman M.E., and Klotman P.E. HIV-associated nephropathy is a late, not early, manifestation of HIV-1 infection. Kidney Int 55 (1999) 1036-1040
53. Perinbasekar S., Brod-Miller C., and Mattana J. Absence of edema in HIV-infected patients with end-stage renal disease. J Acquir Immune Defic Syndr Hum Retrovirol 13 (1996) 368-373
54. Schwartz E.J., and Klotman P.E. Pathogenesis of human immunodeficiency virus (HIV)-associated nephropathy. Semin Nephrol 18 (1998) 436-445
55. Ingulli E., Tejani A., Fikrig S., Nicastri A., Chen C.K., and Pomrantz A. Nephrotic syndrome associated with acquired immunodeficiency syndrome in children. J Pediatr 119 (1991) 710-716
56. Kimmel P.L., Bosch J.P., and Vassalotti J.A. Treatment of human immunodeficiency virus (HIV)-associated nephropathy. Semin Nephrol 18 (1998) 446-458
57. Smith M.C., Pawar R., Carey J.T., Graham Jr. R.C., Jacobs G.H., Menon A., et al. Effect of corticosteroid therapy on human immunodeficiency virus-associated nephropathy. Am J Med 97 (1994) 145-151
58. Watterson M.K., Detwiler R.K., and Bolin Jr. P. Clinical response to prolonged corticosteroids in a patient with human immunodeficiency virus-associated nephropathy. Am J Kidney Dis 29 (1997) 624-626
59. Eustace J.A., Nuermberger E., Choi M., Scheel Jr. P.J., Moore R., and Briggs W.A. Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids. Kidney Int 58 (2000) 1253-1260
60. Wei A., Burns G.C., Williams B.A., Mohammed N.B., Visintainer P., and Sivak S.L. Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition. Kidney Int 64 (2003) 1462-1471
61. Gupta S.K., Eustace J.A., Winston J.A., Boydstun I.I., Ahuja T.S., Rodriguez R.A., et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 40 (2005) 1559-1585
62. Betjes M.G., and Verhagen D.W. Stable improvement of renal function after initiation of highly active anti-retroviral therapy in patients with HIV-1-associated nephropathy. Nephrol Dial Transplant 17 (2002) 1836-1839
63. Szczech L.A., Edwards L.J., Sanders L.L., van der Horst C., Bartlett J.A., Heald A.E., et al. Protease inhibitors are associated with a slowed progression of HIV-related renal diseases. Clin Nephrol 57 (2002) 336-341
64. Wali R.K., Drachenberg C.I., Papadimitriou J.C., Keay S., and Ramos E. HIV-1-associated nephropathy and response to highly-active antiretroviral therapy. Lancet 352 (1998) 783-784
65. Haas M., and Kaul S. Eustace JA: HIV-associated immune complex glomerulonephritis with "lupus-like" features: a clinicopathologic study of 14 cases. Kidney Int 67 (2005) 1381-1390
66. di Belgiojoso G.B., Ferrario F., and Landriani N. Virus-related glomerular diseases: histological and clinical aspects. J Nephrol 15 (2002) 469-479
67. Tabechian D., Pattanaik D., Suresh U., Cohn S.E., and Nadasdy T. Lupus-like nephritis in an HIV-positive patient: report of a case and review of the literature. Clin Nephrol 60 (2003) 187-194
68. Kazi S., Cohen P.R., Williams F., Schempp R., and Reveille J.D. The diffuse infiltrative lymphocytosis syndrome. Clinical and immunogenetic features in 35 patients. AIDS 10 (1996) 385-391
69. Singer D.R., Jenkins A.P., Gupta S., and Evans D.J. Minimal change nephropathy in the acquired immune deficiency syndrome. BMJ 291 (1985) 868
70. Cozzi P.J., Abu-Jawdeh G.M., Green R.M., and Green D. Amyloidosis in association with human immunodeficiency virus infection. Clin Infect Dis 14 (1992) 189-191
71. Joseph A., Wali R.K., and Weinman E.J. Renal amyloidosis in AIDS. Ann Intern Med 133 (2000) 75
72. Pol S., Vallet-Pichard A., and Fontaine H. Hepatitis C and human immune deficiency coinfection at the era of highly active antiretroviral therapy. J Viral Hepat 9 (2002) 1-8
73. Zylberberg H., and Pol S. Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections. Clin Infect Dis 23 (1996) 1117-1125
74. Cacoub P., Renou C., Rosenthal E., Cohen P., Loury I., Loustaud-Ratti V., et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. Medicine 79 (2000) 47-56
75. Wong V.S., Egner W., Elsey T., Brown D., and Alexander G.J. Incidence, character and clinical relevance of mixed cryoglobulinaemia in patients with chronic hepatitis C virus infection. Clin Exp Immunol 104 (1996) 25-31
76. Woitas R.P., Stoschus B., Terjung B., Vogel M., Kupfer B., Brackmann H.H., et al. Hepatitis C-associated autoimmunity in patients coinfected with HIV. Liver Int 25 (2005) 1114-1121
77. Cheng J.T., Anderson Jr. H.L., Markowitz G.S., Appel G.B., Pogue V.A., and D'Agati V.D. Hepatitis C virus-associated glomerular disease in patients with human immunodeficiency virus coinfection. J Am Soc Nephrol 10 (1999) 1566-1574
78. Stokes M.B., Chawla H., Brody R.I., Kumar A., Gertner R., Goldfarb D.S., et al. Immune complex glomerulonephritis in patients coinfected with human immunodeficiency virus and hepatitis C virus. Am J Kidney Dis 29 (1997) 514-525
79. Rustgi V.K., Hoofnagle J.H., Gerin J.L., Gelmann E.P., Reichert C.M., Cooper J.N., et al. Hepatitis B virus infection in the acquired immunodeficiency syndrome. Ann Intern Med 101 (1984) 795-797
80. Maddrey W.C. Hepatitis B - an important public health issue. Clin Lab (Zaragoza) 47 (2001) 51-55
81. Mbulaiteye S.M., Katabira E.T., Wabinga H., Parkin D.M., Virgo P., Ochai R., et al. Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-Cancer Registry Match Study. Int J Cancer 118 (2006) 985-990
82. Fux C.A., Simcock M., Wolbers M., Bucher H.C., Hirschel B., Opravil M., et al. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther 12 (2007) 1165-1173
83. Goicoechea M., Liu S., Best B., Sun S., Jain S., Kemper C., et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 197 (2008) 102-108
84. Izzedine H., Hulot J.S., Vittecoq D., Gallant J.E., Staszewski S., Launay-Vacher V., et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 20 (2005) 743-746
85. Gayet-Ageron A., Ananworanich J., Jupimai T., Chetchotisakd P., Prasithsirikul W., Ubolyam S., et al. No change in calculated creatinine clearance after tenofovir initiation among Thai patients. J Antimicrob Chemother 59 (2007) 1034-1037
86. Antoniou T., Raboud J., Chirhin S., Yoong D., Govan V., Gough K., et al. Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. HIV Med 6 (2005) 284-290
87. Moreno S., Domingo P., Palacios R., Santos J., Falco V., Murillas J., et al. Renal safety of tenofovir disoproxil fumarate in HIV-1 treatment-experienced patients with adverse events related to prior NRTI use: data from a prospective, observational, multicenter study. J Acquir Immune Defic Syndr 42 (2006) 385-387
88. Padilla S., Gutierrez F., Masia M., Canovas V., and Orozco C. Low frequency of renal function impairment during one-year of therapy with tenofovir-containing regimens in the real-world: a case-control study. AIDS Patient Care STDS 19 (2005) 421-424
89. Kalayjian R.C., Franceschini N., Gupta S.K., Szczech L.A., Mupere E., Bosch R.J., et al. Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. AIDS 22 (2008) 481-487
90. Girard P-M, Katlama C, Pialoux G. Atteinte cardiovasculaire au cours de l'infection VIH. In: VIH 2004. Reuil-Malmaison: Doin-Groupe Liaisons SA; 2004. p. 425-37.
91. Barbaro G. Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection. Curr HIV Res 4 (2006) 79-85
92. Carr A., Samaras K., Thorisdottir A., Kaufmann G.R., Chisholm D.J., and Cooper D.A. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353 (1999) 2093-2099
93. Seaberg E.C., Munoz A., Lu M., Detels R., Margolick J.B., Riddler S.A., et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 19 (2005) 953-960
94. Thiebaut R., El-Sadr W.M., Friis-Moller N., Rickenbach M., Reiss P., Monforte A.D., et al. Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antivir Ther 10 (2005) 811-823
95. Palacios R., Santos J., Garcia A., Castells E., Gonzalez M., Ruiz J., et al. Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naive patients. HIV Med 7 (2006) 10-15
96. Szczech L.A., Grunfeld C., Scherzer R., Canchola J.A., van der Horst C., Sidney S., et al. Microalbuminuria in HIV infection. AIDS 21 (2007) 1003-1009
97. Brown T.T., Cole S.R., Li X., Kingsley L.A., Palella F.J., Riddler S.A., et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 165 (2005) 1179-1184
98. Friis-Moller N., Weber R., Reiss P., Thiebaut R., Kirk O., D'Arminio Monforte A., et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 17 (2003) 1179-1193
99. De Wit S., Sabin C.A., Weber R., Worm S.W., Reiss P., Cazanave C., et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 31 (2008) 1224-1229 Epub 2008
100. Periard D., Cavassini M., Taffe P., Chevalley M., Senn L., Chapuis-Taillard C., et al. High prevalence of peripheral arterial disease in HIV-infected persons. Clin Infect Dis 46 (2008) 761-767
101. Sharma A., Holman S., Pitts R., Minkoff H.L., Dehovitz J.A., and Lazar J. Peripheral arterial disease in HIV-infected and uninfected women. HIV Med 8 (2007) 555-560
102. Lorenz M.W., Stephan C., Harmjanz A., Staszewski S., Buehler A., Bickel M., et al. Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis 196 (2008) 720-726
103. Mary-Krause M., Cotte L., Simon A., Partisani M., and Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 17 (2003) 2479-2486
104. Holmberg S.D., Moorman A.C., Williamson J.M., Tong T.C., Ward D.J., Wood K.C., et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 360 (2002) 1747-1748
105. Friis-Moller N., Sabin C.A., Weber R., d'Arminio Monforte A., El-Sadr W.M., Reiss P., et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349 (2003) 1993-2003
106. Friis-Moller N., Weber R., Reiss P., Thiebaut R., Kirk O., d'Arminio Monforte A., et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS 17 (2003) 1179-1193
107. Bozzette S.A., Ake C.F., Tam H.K., Chang S.W., and Louis T.A. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 348 (2003) 702-710
108. Rosso R., Parodi A., d'Annunzio G., Ginocchio F., Nicolini L., Torrisi C., et al. Evaluation of insulin resistance in a cohort of HIV-infected youth. Eur J Endocrinol 157 (2007) 655-659
109. Tebas P., Powderly W.G., Claxton S., Marin D., Tantisiriwat W., Teitelbaum S.L., et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 14 (2000) 63-67
110. Gerntholtz T.E., Goetsch S.J., and Katz I. HIV-related nephropathy: a South African perspective. Kidney Int 69 (2006) 1885-1891
111. Klotman P., and Klotman M. Editorial comment: renal insufficiency in HIV-infected patients may not always be HIVAN. AIDS Read 12 (2002) 273